Trial ID BGB-11417-103 | Maryland Oncology Hematology Trial ID BGB-11417-103 – Maryland Oncology Hematology

Trial ID BGB-11417-103

Trial Information - Phase Ib/II

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Protocol ID: BGB-11417-103

Sponsor: BeiGene USA Inc.

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Hematology

Status

PENDING OPEN

Sponsor

BeiGene USA Inc.
« Clinical Trails Main

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology